InvestorsHub Logo
Followers 3
Posts 191
Boards Moderated 0
Alias Born 04/19/2006

Re: jimsgtx post# 185834

Friday, 08/08/2014 10:42:31 AM

Friday, August 08, 2014 10:42:31 AM

Post# of 346136

Two additional firms are particularly troubled. Peregrine Pharmaceuticals PPHM +0.32% lead drug bavituximab, a monoclonal antibody turned I-O, is in Phase III for NSCLC but critics question improvements following lackluster and unreliable Phase II data, and wonder why more robust statistical information is not provided.



hmmm, devil is in the details?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News